Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


2011 Scrip 100: Oncology trials

This article was originally published in Scrip

Executive Summary

Between 1 October 2009 and 30 September 2010, there were 428 new Phase II to Phase III clinical trials initiated by industry sponsors in the oncology arena. Non-small cell lung cancer was the clear disease focus, accounting for 11% of these new trials. Breast cancer, multiple haematological cancers, non-Hodgkin's lymphoma and colorectal cancer rounded out the top five disease areas, together accounting for 35% (147) of the total trials initiated.



Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts